Company: STAA
Filing Date: 2025-09-16
Form Type: DEFM14A
Source: 0001193125-25-204396
Chunk: 82

Company: STAAR SURGICAL CO
Filing Date: 2025-09-16
Form: DEFM14A
Chunk 82
---
 receive certain required regulatory approvals (as discussed in the section of this proxy statement titled “The Merger 
 Agreement—Efforts to Close the Merger”);                                                                                                                                                                                              |

| • |     | STAAR’s ability to seek specific performance of Alcon’s and Merger Sub’s obligations to cause                      
 the Merger to occur and to prevent breaches of the Merger Agreement, subject to the terms of the Merger Agreement; |

| • |     | STAAR management’s view that STAAR has sufficient operating flexibility under the terms of the Merger 
 Agreement to conduct its business prior to the consummation of the Merger; and                        |

| • |     | the fact that the definition of “Material Adverse Effect” excludes certain types of events,                                                                                                                                          
 occurrences, circumstances and changes, including changes in international tariffs, trade policies, sanctions, applicable law or any “trade wars” except to the extent such changes have (or would reasonably be expected to have) a 
 disproportionate and adverse effect on STAAR relative to other medical device companies in similar geographies.                                                                                                                      |

| • |     | Likelihood of Completion. The Board considered the likelihood that the Merger would be consummated based                                                                                                                                          
 on, among other things, Alcon’s ability to complete large acquisition transactions, the lack of a financing condition, the limited number and nature of conditions required to be satisfied in order to consummate the Merger and the expectation 
 of obtaining required regulatory approvals on a timely basis.                                                                                                                                                                                     |

| • |     | Timing of Completion. The Board considered the anticipated timing of the consummation of the Merger and                                                                                                                                             
 the expectation that the Merger could be consummated in a reasonable timeframe and in an orderly manner, reducing the period during which STAAR’s business would be subject to the potential uncertainty of closing and expediting the timeline for 
 STAAR stockholders to receive the Merger Consideration.                                                                                                                                                                                             |

| • |     | Stockholder Vote. The Board considered the fact that the consummation of the Merger would be subject to                                                                                                                                                 
 the adoption of the Merger Agreement by STAAR stockholders, and STAAR stockholders would be free to reject the proposed Merger by voting against the adoption of the Merger Agreement for any reason, including if a higher offer were to be made prior 
 to the Special Meeting, and that STAAR would not be required to pay Alcon a termination fee or expense reimbursement due to a failure of STAAR stockholders to adopt the Merger